Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy.

Workenhe ST, Mossman KL.

Oncoimmunology. 2013 Dec 1;2(12):e27138. Epub 2013 Dec 9.

2.

Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Workenhe ST, Mossman KL.

Mol Ther. 2014 Feb;22(2):251-6. doi: 10.1038/mt.2013.220. Epub 2013 Oct 19. Review.

3.

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances.

Simpson GR, Relph K, Harrington K, Melcher A, Pandha H.

Oncolytic Virother. 2016 Jan 6;5:1-13. doi: 10.2147/OV.S66083. eCollection 2016. Review.

4.

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.

Guo ZS, Liu Z, Bartlett DL.

Front Oncol. 2014 Apr 10;4:74. doi: 10.3389/fonc.2014.00074. eCollection 2014. Review.

5.

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.

Moehler M, Goepfert K, Heinrich B, Breitbach CJ, Delic M, Galle PR, Rommelaere J.

Front Oncol. 2014 May 1;4:92. doi: 10.3389/fonc.2014.00092. eCollection 2014. Review.

6.

Virus combinations and chemotherapy for the treatment of human cancers.

Kumar S, Gao L, Yeagy B, Reid T.

Curr Opin Mol Ther. 2008 Aug;10(4):371-9. Review.

PMID:
18683102
7.

Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.

Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC, Park BH, Kirn DH, Hwang TH.

Sci Transl Med. 2013 May 15;5(185):185ra63. doi: 10.1126/scitranslmed.3005361.

8.

Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.

Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH.

Neoplasia. 2012 Dec;14(12):1115-21.

9.

Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.

Li QX, Liu G, Zhang X.

Curr Pharm Biotechnol. 2012 Jul;13(9):1773-85. Review.

PMID:
21740353
10.

Oncolytic virotherapy.

Russell SJ, Peng KW, Bell JC.

Nat Biotechnol. 2012 Jul 10;30(7):658-70. doi: 10.1038/nbt.2287. Review.

11.

Trial watch: Oncolytic viruses for cancer therapy.

Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Jun 1;2(6):e24612. Epub 2013 Apr 16.

12.

Oncolytic HSV as a vector in cancer immunotherapy.

Li H, Zhang X.

Methods Mol Biol. 2010;651:279-90. doi: 10.1007/978-1-60761-786-0_16.

PMID:
20686972
13.

Immunotherapeutic potential of oncolytic vaccinia virus.

Thorne SH.

Immunol Res. 2011 Aug;50(2-3):286-93. doi: 10.1007/s12026-011-8211-4. Review.

PMID:
21717084
14.

[Current state of oncolytic virotherapy in Japan].

Nakamori M, Yamaue H.

Gan To Kagaku Ryoho. 2013 May;40(5):553-8. Review. Japanese.

PMID:
23863576
15.

Trial watch: Immunostimulatory cytokines in cancer therapy.

Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jun 3;3:e29030. eCollection 2014.

16.

Targeting autophagy to enhance oncolytic virus-based cancer therapy.

Meng S, Xu J, Wu Y, Ding C.

Expert Opin Biol Ther. 2013 Jun;13(6):863-73. doi: 10.1517/14712598.2013.774365. Epub 2013 Mar 14. Review.

PMID:
23488666
17.

Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses.

Angarita FA, Acuna SA, Ottolino-Perry K, Zerhouni S, McCart JA.

Trends Mol Med. 2013 Jun;19(6):378-92. doi: 10.1016/j.molmed.2013.02.008. Epub 2013 Mar 27. Review.

PMID:
23540715
18.

Oncolytic virotherapy for neuroblastoma.

Ramírez M, García-Castro J, Alemany R.

Discov Med. 2010 Nov;10(54):387-93. Review.

19.
20.

Molecular pathways: multimodal cancer-killing mechanisms employed by oncolytic vesiculoviruses.

Mahoney DJ, Stojdl DF.

Clin Cancer Res. 2013 Feb 15;19(4):758-63. doi: 10.1158/1078-0432.CCR-11-3149. Epub 2012 Dec 26. Review.

Items per page

Supplemental Content

Write to the Help Desk